Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
November 23 2022 - 8:00AM
Business Wire
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell
immunotherapy, leveraging its novel allogeneic Epstein-Barr virus
(EBV) T-cell platform to develop transformative therapies for
patients with cancer and autoimmune diseases, today announced that
Pascal Touchon, President and Chief Executive Officer, will
participate in a virtual fireside chat at the Evercore ISI 5th
Annual HealthCONx Conference on Wednesday, November 30, 2022, at
2:15 p.m. EST.
A live webcast of the fireside chat will be available by
visiting the Investor Events and Presentations section of
atarabio.com. An archived replay of the webcast will be available
on the Company's website for 30 days following the live
presentation.
About Atara Biotherapeutics, Inc. Atara Biotherapeutics,
Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging
its novel allogeneic EBV T-cell platform to develop transformative
therapies for patients with serious diseases including solid
tumors, hematologic cancers and autoimmune disease. With our lead
program receiving a CHMP positive opinion for a marketing
authorization in Europe, Atara is the most advanced allogeneic
T-cell immunotherapy company and intends to rapidly deliver
off-the-shelf treatments to patients with high unmet medical need.
Our platform leverages the unique biology of EBV T cells and has
the capability to treat a wide range of EBV-associated diseases, or
other serious diseases through incorporation of engineered CARs
(chimeric antigen receptors) or TCRs (T-cell receptors). Atara is
applying this one platform, which does not require TCR or HLA gene
editing, to create a robust pipeline including: tab-cel in Phase 3
development for Epstein-Barr virus-driven post-transplant
lymphoproliferative disease (EBV+ PTLD) and other EBV-driven
diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as
a potential treatment for multiple sclerosis; and multiple
next-generation chimeric antigen receptor T-cell (CAR-T)
immunotherapies for both solid tumors and hematologic malignancies.
Improving patients’ lives is our mission and we will never stop
working to bring transformative therapies to those in need. Atara
is headquartered in Southern California. For additional information
about the company, please visit atarabio.com and follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221123005075/en/
INVESTORS & MEDIA: Investors Eric Hyllengren
805-395-9669 ehyllengren@atarabio.com Media Alex Chapman
805-456-4772 achapman@atarabio.com
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Atara Biotherapeutics (NASDAQ:ATRA)
Historical Stock Chart
From Jul 2023 to Jul 2024